Dermatologists are warning consumers that the harmless-looking, henna tattoos that are being sold everywhere from summer carnivals and open-air malls to cruise ships and vacation hot spots could contain a harmful chemical known as para-phenylenediamine, or PPD, used to create longer-lasting black henna tattoos. Notably, PPD has been associated with a rash of major skin [ Read More ]
Archive for July, 2008
New NMA President to Address Cancer and Mental Health Disparities Delivering her inaugural address as the 109th president of the National Medical Association (NMA), Carolyn Barley Britton, M.D., M.S., shared her plans to focus on cancer and mental health disparities during her administration. The NMA is the nation’s premier organization for African American physicians. Dr. [ Read More ]
A recent AHPMA survey among continence care professionals has painted a bleak picture on the current state of many continence services in the UK, largely due to lack of Government funding. The survey finds that continence care staff are striving for quality care within extremely limited resources. The survey received 148 responses, which show an [ Read More ]
Riverside Partners, based in Boston, MA, is pleased to announce that it has partnered with management to acquire HealthDrive (“HealthDrive” or the “Company”). HealthDrive is the leading provider of multi-specialty, on-site healthcare services to residents of extended care facilities. HealthDrive’s multi modality business model brings top quality dentistry, optometry, podiatry and audiology services directly to [ Read More ]
MRI and advanced computer analysis bring us closer to early identification of Alzheimer’s For the first time, scientists have captured images of brain lesions similar to those found in Alzheimer’s disease using clinical-grade MRI in an animal model of the disease, according to research reported today at the Alzheimer’s Association’s 2008 International Conference on Alzheimer’s [ Read More ]
First and only drug therapy to address major Chinese health concern Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the State Food and Drug Administration (SFDA) of China has approved Nexavar(R) (sorafenib) tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer. Nexavar is the first and [ Read More ]